The Estée Lauder Companies will acquire Korea-based Have & Be Co. Ltd., the company behind Dr. Jart+ and Do The Right Thing.

NEW YORK -Tuesday 19 November 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- The Estée Lauder Companies Inc. (NYSE: EL) announced today that it has signed an agreement to acquire the shares that it does not already beneficially own in Have & Be Co. Ltd., the Seoul-based, global skin care company behind Dr. Jart+ and men’s grooming brand Do The Right Thing. Expected to close in December 2019, the acquisition follows the Company’s December 2015 minority investment in Have & Be Co. Ltd. and is pursuant to an agreement made at that time. As one of the fastest growing skin care brands globally, Dr. Jart+ is expected to help further strengthen The Estée Lauder Companies’ leadership position in skin care, and will especially help expand the Company’s consumer reach in Asia/Pacific, North America, the United Kingdom and trave ... Read more »

NEW YORK -Tuesday 19 November 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today that it is proposing to issue $250.0 million aggregate amount of senior unsecured notes due 2029 (the “notes”) in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The notes will constitute a further issuance of, be fully fungible with, rank equally with and form a single series with the $500.0 million aggregate principal amount of the 4.000% senior notes due 2029 issued on November 7, 2019. The proposed offering is subject to market and other conditions. If the offering is successfully placed, MSCI intends to use the net proceeds from the offering, together with available cash, for the partial redemption, in an amount equal to the aggregate issue amount of th ... Read more »

Alpha Prime Delivers Unrivaled Combination of Field-of-View, Range, High-Resolution, Clarity and Operational Performance

SAN JOSE, Calif.-Sunday 17 November 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Velodyne Lidar, Inc. today introduced Alpha Prime™, the next generation lidar sensor utilizing Velodyne’s patented surround view technology to deliver the combined highest performance specifications for the autonomous mobility industry in one sensor. The sensor is an unmatched solution in perception, field-of-view and range for autonomous markets including transportation, trucking and robotics. Offering a new level of power efficiency, the Alpha Prime is available now for orders and delivery.

The Alpha Prime’s unique combination of breakthrough innovations allows vehicles to navigate in unfamiliar and dynamic settings. Its best-in-class capabilities help improve vehicle safety and enable more precise mapping. These include:

   ... Read more »

30+ Olympic and Paralympic hopefuls descend upon San Francisco today for the Team Visa Summit

Simone Biles (Gymnastics, USA), Katie Ledecky (Swimming, USA), Kanoa Igarashi (Surfing, Japan), Poppy Starr Olsen (Skateboarding, Australia), Teresa Perales (Para Swimming, Spain) and PV Sindhu (Badminton, India) join Team Visa Tokyo 2020

SAN FRANCISCO-Thursday 14 November 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Visa (NYSE: V), the Worldwide Payment Technology Partner of the Olympic and Paralympic Games, today announced its most diverse roster of athletes on Team Visa Tokyo 2020. Representing 43 countries, the most in Team Visa history, the current roster is comprised of 70+ athletes across 30+ sports, including new additions to The Games: Surfing, Skateboarding and Sport Climbing.

The announcement was made at the Team Visa Summit, hosted at the company’s San Francisco Innovation Center. The Summit offers athletes resources on how to improve financial li ... Read more »

• This analysis on effectiveness also shows empagliflozin was associated with a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors or GLP-1 receptor agonists1

• A second analysis on healthcare resource utilisation shows empagliflozin was associated with a reduced risk in all-cause hospitalisations compared with DPP-4 inhibitors2

INGELHEIM, Germany and INDIANAPOLIS, US-Monday 18 November 2019 [AETOS Wire]

(BUSINESS WIRE) -- A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that empagliflozin was associated with a decreased risk of hospitalisation for heart failure and a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors and GLP-1 receptor agonists.1 The interim analysis included 190,000 adults in the US with type 2 diabetes with and without cardiovascular disease. ... Read more »